AZmed Revolutionizes Medical Imaging with €15 Million Funding
February 21, 2024, 10:04 am
AZmed, a Paris-based MedTech startup, has secured a groundbreaking €15 million in Series A funding to propel the future of medical imaging with artificial intelligence. Investors like Maison Worms, Techstars, and Teampact Ventures have joined forces to support AZmed's mission of enhancing radiologists' workflows and transforming patient care pathways.
In a world where healthcare professionals are recognizing the power of AI, AZmed stands out as a pioneer in the field. Their AI software, Rayvolve, has already made waves by obtaining CE marking for fracture detection on X-rays in 2019 and FDA clearance in 2022. This innovative technology has been adopted by over 1,000 healthcare facilities across 40 countries, including renowned institutions like the NHS and UH Cleveland Medical Center.
With this funding, AZmed is poised to solidify its leadership in Europe and expand its reach globally, including in the United States, the Middle East, Africa, and Asia. The startup plans to double its workforce and ramp up research and development efforts to further enhance its AI software, offering a comprehensive range of medical imaging solutions.
Julien Vidal, the CEO of AZmed, expressed his excitement about the funding, emphasizing the critical role of AI in modern healthcare. He highlighted the need for every medical image to be paired with an AI diagnosis to streamline workflows and improve patient outcomes. Investors like Maison Worms recognize the potential of AZmed's technology to revolutionize healthcare and are eager to support its journey towards transforming the industry.
AZmed's innovative approach to medical imaging is reshaping the landscape of radiology, empowering healthcare professionals with cutting-edge AI solutions. As the company continues to push boundaries and drive innovation, the future of medical imaging looks brighter than ever.
In a world where healthcare professionals are recognizing the power of AI, AZmed stands out as a pioneer in the field. Their AI software, Rayvolve, has already made waves by obtaining CE marking for fracture detection on X-rays in 2019 and FDA clearance in 2022. This innovative technology has been adopted by over 1,000 healthcare facilities across 40 countries, including renowned institutions like the NHS and UH Cleveland Medical Center.
With this funding, AZmed is poised to solidify its leadership in Europe and expand its reach globally, including in the United States, the Middle East, Africa, and Asia. The startup plans to double its workforce and ramp up research and development efforts to further enhance its AI software, offering a comprehensive range of medical imaging solutions.
Julien Vidal, the CEO of AZmed, expressed his excitement about the funding, emphasizing the critical role of AI in modern healthcare. He highlighted the need for every medical image to be paired with an AI diagnosis to streamline workflows and improve patient outcomes. Investors like Maison Worms recognize the potential of AZmed's technology to revolutionize healthcare and are eager to support its journey towards transforming the industry.
AZmed's innovative approach to medical imaging is reshaping the landscape of radiology, empowering healthcare professionals with cutting-edge AI solutions. As the company continues to push boundaries and drive innovation, the future of medical imaging looks brighter than ever.